Publication | Closed Access
Prospective clinical trial of disulfiram plus copper in men with metastatic castration‐resistant prostate cancer
22
Citations
24
References
2022
Year
Oral DSF is not an effective treatment for mCRPC due to rapid metabolism into an inactive metabolite, Me-DDC. This trial has stopped enrollment and further work is needed to identify a stable DSF formulation for treatment of mCRPC.
| Year | Citations | |
|---|---|---|
Page 1
Page 1